Hepatitis C News Ticker; Preliminary Testing Of New Drug Against Hepatitis C Shows Good Promise

New On The Web Site

Tuesday, September 06, 2011 10:36 AM

Preliminary Testing Of New Drug Against Hepatitis C Shows Good Promise
Researchers are reporting that a sedate is showing commitment in early testing as a imaginable new treatment for hepatitis C, a stubborn and potentially deadly liver ailment. It’s too prematurely to tell if the drug actually works, and it will be years before it’s ready to seek federal leave to be prescribed to patients. Still, the drug – or others like it in development – could sum up to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr Eugene R Schiff, steersman of the University of Miami’s Center for Liver Diseases......

HCV entry receptor as potential targets for siRNA based inhibition of HCV
Hepatitis C virus (HCV) is a major health concern with almost 3% of the world's population (350 million individuals) and 10% of the Pakistani population chronically infected with this viral pathogen. The current therapy of interferon-alpha and ribavirin against HCV has limited efficiency, so alternative options are desperately needed

Breastfeeding of Newborns by Mothers Carrying Hepatitis B Virus
http://archpedi.ama-assn.org/cgi/content/short/165/9/837?rss=1
Objective To perform a systematic review of prospective studies to confirm the role of breastfeeding in mother-to-child transmission of hepatitis B virus .

Pharmasset Announces 91% SVR12 From the PROTON Trial in Subjects With Hepatitis C Genotype 1

Dramatic Changes in Hepatitis C Treatment Expected to Continue
Next in the development queue are three agents that entered Phase III development this year, including two additional protease inhibitors (TMC435 from Johnson & Johnson’s Tibotec unit and BI201335 from Boehringer Ingelheim) and a cyclophilin inhibitor that disrupts a host function required for viral replication (alisporivir from Novartis)........

Jennerex Presents Interim Clinical Data of JX-594 Followed by Sorafenib Demonstrating Tumor Responses in Liver Cancer
"The promising clinical data reported today, combined with the encouraging data we reported in May from our randomized Phase 2 trial of JX-594 in advanced liver cancer, strongly support our plans to further advance this exciting product into late-stage clinical development," stated David H. Kirn, M.D., president and chief executive officer of Jennerex. "We look forward to initiating enrollment for TRAVERSE, our global, randomized Phase 2b trial of JX-594 in advanced liver cancer in the coming months."

The Problem Of The Use Of Unproven Dietary Supplements
US fitness authorities Wednesday intensified pressurize on makers of dietary supplements, indication individuals or companies marketing “tainted” products that they could face criminal prosecution, among other consequences. The arouse comes after several reports of injury and even death from the use of illegal supplements that are deceptively labeled or repress undeclared ingredients.

Low doses of acetylsalicylic acid increase risk of GI bleeding
9/6/2011 GastroHep.com News
Low doses of acetylsalicylic acid increase risk of GI bleeding, reports the most recent issue of Clinical Gastroenterology Hepatology.

PEG-IFN and Ribavirin for Patients With HCV Genotype 6a
What is the standard treatment for patients with HCV-6 infection? Is a combination of pegylated interferon and an antiviral considered optimal?
Journal of Viral Hepatitis, September 2011

Liver Transplant Recipients with Chronic Hepatitis C
Recurrence of HCV is nearly universal in liver transplant recipients and is associated with significant complications. Which therapy is more likely to prevent it?American Journal of Transplantation, September 2011

Influenza Vaccination in the U.S., 2011–2012
On August 18, the CDC released guidance for use of influenza vaccines for the 2011–2012 influenza season, based on recommendations from the Advisory Committee on Immunization Practices. Vaccination of all individuals in the U.S. aged 6 months continues to be recommended. The vaccine virus strains are the same as those for the 2010–2011 season. Nonetheless, for optimal protection against influenza, annual immunization is recommended — even for persons who received the vaccine last year.
Details can be found at http://www.cdc.gov/mmwr/pdf/wk/mm6033.pdf.

Walnuts Reduce Breast Cancer Risk By Half In Animal Studies
06 September 2011
Mice fed a diet that included daily walnuts had half the risk of developing breast cancer compared to those on a typical diet, researchers from Marshal University School of Medicine reported in the journal Nutrition and Cancer. Elaine Hardman, Ph.D...

Metabolic Syndrome Prevented By Powerful Antioxidant Resveratrol In Lab Tests
05 September 2011
Researchers in the Faculty of Medicine & Dentistry at the University of Alberta have discovered that resveratrol, a powerful antioxidant found in common foods, prevents a syndrome in some offspring that could lead to later...